Valentine’s Day has come and gone, but it’s never too late to focus on your heart health.  A groundbreaking new study ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

February is American Heart Month -- a time dedicated to raising awareness about heart disease, the leading cause of death in ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Cardiovascular diseases claim more lives in the U.S. than all forms of cancer and accidental deaths combined, according to ...

American Indian and Alaska Native communities are some of the most underserved minoritized groups in the United States, and ...

To maintain a healthy heart, researchers say people should focus on diet and exercise, limit alcohol, manage stress, get ...

Recent reports reveal heart disease is the leading cause of death in the U.S., many of whom are younger than 45. Here's what ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...